Paragraph 2
United Kingdom
In this Schedule—
“Declaration of Helsinki” means the Declaration of Helsinki adopted by the World Medical Assembly in June 1964 F1...;
“guardian” shall be construed in accordance with section 51(8) of the Adults with Incapacity (Scotland) Act 2000 M1;
“legal representative” means, in relation to a minor or to an adult unable by virtue of physical or mental incapacity to give informed consent, and who is, or is being considered as, F2a participant for a clinical trial—
- (a)
in relation to adults and minors in England, Wales and Northern Ireland, and minors in Scotland—
- (i)
a person, other than a person F3connected with the conduct of the trial, who—
- (aa)
by virtue of their relationship with that adult or that minor, is suitable to act as their legal representative for the purposes of that trial, and
- (bb)
is available and willing to so act for those purposes, or
- (aa)
- (ii)
if there is no such person, a person, other than a person connected with the conduct of the clinical trial, who is—
- (aa)
the doctor primarily responsible for the medical treatment provided to that adult F4or that minor, or
- (bb)
a person nominated by the relevant health care provider; and
- (aa)
- (i)
- (b)
in relation to adults in Scotland—
- (i)
any guardian or welfare attorney who has power to consent to the adult’s participation in research, or
- (ii)
if there is no such guardian or welfare attorney, the adult’s nearest relative, or
- (iii)
if it is not reasonably practicable to contact a guardian or welfare attorney or the adult’s nearest relative before the decision to enter the adult as a participant of the clinical trial is made, a person, other than a person connected with the conduct of the clinical trial, who is—
- (aa)
the doctor primarily responsible for the medical treatment provided to that adult, or
- (bb)
a person nominated by the relevant health care provider;
- (aa)
- (i)
- (a)
“nearest relative” has the meaning given by section 87(1) of the Adults with Incapacity (Scotland) Act 2000;
“parental responsibility”—
“person connected with the conduct of the trial” means—
- (a)
the sponsor of the trial,
- (b)
a person employed or engaged by, or acting under arrangements made with, the sponsor and who undertakes activities in connection with the management of the trial,
- (c)
an investigator for the trial,
- (d)
a health care professional who is a member of an investigator’s team for the purposes of the trial, or
- (e)
a person who provides health care under the direction or control of a person referred to in paragraphs (c) and (d) above, whether in the course of the trial or otherwise;
- (a)
“relevant health care provider” means—
- (a)
in relation to a person receiving services in pursuance of the National Health Service Act 1977 M5, the National Health Service (Scotland) Act 1978 M6, or the Health and Personal Social Services (Northern Ireland) Order 1972 M7—
- (i)
in a case where a health service body is providing those services, that body, or
- (ii)
in any other case, the health service body which entered the arrangements under which those services are provided, or
- (i)
- (b)
in relation to any other person receiving health care, the person primarily responsible for providing that health care; and
- (a)
“welfare attorney” shall be construed in accordance with section 51(8) of the Adults with Incapacity (Scotland) Act 2000.
Annotations
Textual amendments
- F1
Words in Sch. 1 Pt. 1 para. 2 omitted (28.4.2026) by virtue of The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 37(3)(e)
- F2
Words in Sch. 1 Pt. 1 substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 37(3)(c)
- F3
Words in Sch. 1 Pt. 1 para. 2 substituted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 27(1)(i)(aa)
- F4
Words in Sch. 1 Pt. 1 para. 2 inserted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 27(1)(i)(bb)
- F5
Word in Sch. 1 Pt. 1 para. 2 substituted (29.8.2006) by The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006 (S.I. 2006/1928), regs. 1(1), 27(1)(ii)
Marginal citations
- M1
- M2
1989 c. 41; see, in particular, sections 3(1) and 5(6).
- M3
1995 c. 36; see, in particular, sections 1(3) and 7(5).
- M4
S.I. 1995/755 (N.I.2); see, in particular, article 6.
- M5
- M6
- M7
Notes on Schedule 1
Textual amendments
- F1
Word in Sch. 1 heading substituted (28.4.2026) by The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (S.I. 2025/538), regs. 1(2), 37(2)